Latest Oncology News

Bel-Sar Elicits Complete Responses in NMIBC

Bel-Sar Elicits Complete Responses in NMIBC

October 17th 2024

Chris Ryan

Belzupacap sarotalocan produced complete responses in patients with low-grade non–muscle-invasive bladder cancer.

ARANOTE Data Highlight Darolutamide Plus ADT as a Potential Chemo-Free Option in mHSPC

ARANOTE Data Highlight Darolutamide Plus ADT as a Potential Chemo-Free Option in mHSPC

October 17th 2024

Jax DiEugenio

Fred Saad, MD, FRCS, discusses efficacy and safety data for darolutamide plus ADT in metastatic hormone-sensitive prostate cancer.

FDA Approval Insights: Denileukin Diftitox in Relapsed/Refractory CTCL

FDA Approval Insights: Denileukin Diftitox in Relapsed/Refractory CTCL

October 17th 2024

Francine Foss, MD

Dr Foss discusses the significance of the FDA approval of denileukin diftitox for patients with relapsed/refractory CTCL.

Cabozantinib Plus Atezolizumab Fails to Improve OS Over Subsequent Novel Hormonal Therapy in mCRPC

Cabozantinib Plus Atezolizumab Fails to Improve OS Over Subsequent Novel Hormonal Therapy in mCRPC

October 17th 2024

Courtney Flaherty

Cabozantinib plus atezolizumab did not produce superior OS outcomes vs a second novel hormonal therapy in metastatic castration-resistant prostate cancer.

Daratumumab/Lenalidomide Maintenance Deepens Responses, Boosts MRD-Negativity Rates in Myeloma After ASCT

Daratumumab/Lenalidomide Maintenance Deepens Responses, Boosts MRD-Negativity Rates in Myeloma After ASCT

October 17th 2024

Courtney Flaherty

Ashraf Z. Badros, MBCHB, discusses the use of daratumumab plus lenalidomide as maintenance therapy after transplant in newly diagnosed multiple myeloma.

Latest Oncology Videos

Dr Gordon on Next Steps for Optimizing Liso-Cel Use in R/R MCL
Optimizing Treatment for Advanced EGFR-Mutated NSCLC: FLAURA2, Toxicity Management, and ctDNA
Dr Nowakowski on the Significance of the TakeAim Lymphoma Trial in PCNSL
Impact of Prior BTKi vs BCL2i Therapy on Treatment Decision-Making in CLL
Key Takeaways for Concurrent Biomarker Testing in NSCLC
Dr Friedlander on Emerging Agents of Interest in Urothelial Cancer
Dr Nowakowski on the Implications of the FDA Approval of Epcoritamab in Follicular Lymphoma
Dr Corre on the Rationale for the CASSIOPEIA Trial in Newly Diagnosed Myeloma
Dr Amanam on Currently Available JAK Inhibitors for Myelofibrosis
Dr Scandura on the SENTRY-2 Trial of Single-Agent Selinexor in JAK Inhibitor–Naive Myelofibrosis
Dr Klisovic on a Case Discussion of Momelotinib in Myelofibrosis With Anemia
Dr Lorusso on Key Takeaways About Relacorilant Combination Treatment in Ovarian Cancer
Dr Lin on the Importance of the DESTINY-Breast12 Trial for T-DXd Use in HER2+ Breast Cancer With Brain Metastases
Dr Lee on the Significance of the Tumor-Agnostic Approval of T-DXd for HER2+ Urothelial Cancer
Clinical Insights on Osimertinib in Frontline Therapy for EGFR-Mutated NSCLC
The Current Treatment Landscape for R/R CLL
Dr Sallman on the Significance of the FDA Approval of Frontline Luspatercept for Lower-Risk MDS
Dr Gluz on the Rationale for the WSG-TP-II Trial in HR+/HER2+ Early Breast Cancer
Dr Weinberg on the Prognostic Use of ctDNA Testing in Resected CRC
Dr Ashraf on Ivonescimab vs Pembrolizumab as a First-Line Treatment for PD-L1+ Advanced NSCLC
Dr Tao on the Efficacy of Avelumab/Cetuximab/Radiotherapy in Cisplain-Eligibile vs Ineligible HNSCC
Dr Weiss on Outcomes With Versamune HPV Plus Pembrolizumab in HPV16+ HNSCC
Dr Sonpavde on an Exploratory Analysis of CheckMate 901 in Metastatic Urothelial Cancer

All Oncology News

Updated RAMP 201 Data to Support NDA Submission for Avutometinib/Defactinib Combo in Recurrent KRAS+ Ovarian Cancer

October 17th 2024

Chris Ryan

Updated RAMP 201 data will support an NDA submission to the FDA for avutometinib plus defactinib in recurrent low-grade serous ovarian cancer.

Tafasitamab Plus Lenalidomide Wins Approval in Mexico for ASCT-Ineligible, R/R DLBCL

October 17th 2024

Ashling Wahner

Tafasitamab plus lenalidomide followed by tafasitamab monotherapy has been approved in Mexico for ASCT-ineligible, relapsed/refractory DLBCL.

Fox Chase Cancer Center Becomes Philadelphia’s First Comprehensive Radiopharmaceutical Therapy Center of Excellence

October 17th 2024

Fox Chase Cancer Center

Jian Q. “Michael” Yu, MD, FRCPC, FACNM, is Chief of Nuclear Medicine/PET at Fox Chase, which was recently named Philadelphia’s first Comprehensive Radiopharmaceutical Therapy Center of Excellence.

Asciminib Yields Promising Efficacy vs SOC Agents in CML

October 17th 2024

Megan Hollasch

Jorge Cortes, MD, details how asciminib could affect care for patients with CML, diving into key takeaways from the ASC4FIRST trial.

Experts Highlight Noteworthy Research From the 2024 ESMO Congress

October 17th 2024

Ashling Wahner

Oncology experts share notable clinical trials and up-and-coming therapies presented at the 2024 ESMO Congress.

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

October 16th 2024

Chandler Park, MD, MSc, FACP

Drs Park and Patil delve into the evolving SCLC treatment paradigm by examining data from recent studies and focus on treatment developments for patients with ALK-positive NSCLC.

T-DXd Demonstrates Efficacy in HER2+ Metastatic Breast Cancer With Stable or Active Brain Metastases

October 16th 2024

Dana-Farber Cancer Institute

Nancy U. Lin, MD, discusses findings from the DESTINY-Breast12 trial of trastuzumab deruxtecan in advanced HER2-positive breast cancer with brain metastases.

Donor Clonal Hematopoiesis May Predict Post-Transplant Relapse and Outcomes in Hematologic Malignancies

October 16th 2024

Courtney Flaherty

Screening for donor-derived clonal hematopoiesis may have prognostic value for outcomes following auto-HSCT in patients with hematologic malignancies.

Venetoclax/Rituximab Retreatment Produces Durable Responses in CLL

October 16th 2024

Ashling Wahner

Retreatment with venetoclax plus rituximab generated responses in patients with CLL who had responded to and progressed after initial venetoclax treatment.

Roswell Park Radiation Oncologist Highlights New Insights on Single-Fraction Radiation for Central Lung Tumors

October 16th 2024

Roswell Park Comprehensive Cancer Center

Study featured at ASTRO 2024 is one of the first to assess single-fraction SBRT for centrally located lung cancers

Osimertinib Plus Savolitinib Generates Durable Responses in EGFR-Mutant, MET-Amplified NSCLC

October 16th 2024

Courtney Flaherty

Adding savolitinib to osimertinib produced clinically meaningful responses in EGFR-mutant, MET-overexpressed NSCLC following progression on osimertinib.

VCN-01 Earns Orphan Medicinal Product Designation in Europe for Retinoblastoma

October 16th 2024

Chris Ryan

The European Commission has granted orphan medicinal product designation to VCN-01 for the treatment of patients with retinoblastoma.

McKesson's Patient-Reported Outcomes Measure Will Track Improvements in Health-Related Social Needs

October 16th 2024

Erin Crum, MPH

The use of patient-reported outcome measures—the gold standard in quality measurement—is crucial to building a patient-centered, value-based care system.

Galinpepimut-S Earns FDA Rare Pediatric Disease Designation for AML

October 16th 2024

Chris Ryan

The FDA has granted rare pediatric disease designation to galinpepimut-S for acute myeloid leukemia.

Accurate Diagnosis of dMMR/MSI-H Status Is Key for Nivolumab/Ipilimumab Treatment in mCRC

October 16th 2024

Jax DiEugenio

Thierry André, MD, discusses findings from subgroup analyses of the CheckMate 8HW trial of nivolumab/ipilimumab in dMMR/MSI-H metastatic colorectal cancer.

See All News